Regulatory Approval
Regulatory Approval - Related Videos
01:26
FDA Approved Drugs: Changes to Approved Drugs
0 Views •
2025
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
02:02
Cis-regulatory Sequences
0 Views •
2020
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
0 Views •
Cited by 2 •
2007
05:05
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
0 Views •
Cited by 95 •
2011
We describe a technique for labeling and tracking stem cells with FDA-approved, superparamagnetic iron oxide (SPIO), ferumoxytol (Feraheme). This cellular imaging technique that utilizes magnetic resonance (MR) imaging for visualization, is readily accessible for long-term monitoring and diagnosis of successful or unsuccessful stem cell engraftments in patients.
10:03
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
0 Views •
Cited by 24 •
2013
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
FAQs
Statistical analysis makes uncertainty visible rather than treating an observed result as conclusive by itself. Probability models and confidence intervals describe the range of effects compatible with the collected data, while hypothesis testing evaluates evidence against a predefined assumption. This helps regulators judge how reliable an estimated benefit is when weighing it against potential risks for the intended use.
Predefined endpoints connect the research question to a measurable outcome before results are assessed. Their evaluation allows reviewers to determine whether the product achieved the outcome that the study was designed to examine, rather than relying on an unplanned finding. In regulatory approval, this alignment supports consistent interpretation of clinical-trial evidence and reduces ambiguity in decisions about effectiveness.
Subgroup analysis examines whether results differ across specified portions of the study population. Within regulatory review, it can add context about how consistently an observed treatment effect appears across groups, but its value depends on the available data and the way the analysis was planned. These comparisons help place overall trial findings in a broader population context.
Sample-size planning determines how much information a study should collect to evaluate its endpoints meaningfully. It is part of the statistical design used before data are gathered, alongside the selection of analyses and uncertainty measures. Adequate planning helps ensure that laboratory, clinical-trial, or manufacturing data can contribute useful evidence when regulators assess quality, safety, and effectiveness.
Evidence for a regulatory decision can come from several stages, including laboratory studies, clinical trials, and manufacturing tests. Statistical methods provide a common way to analyze these different data sources, although the relevant measurements and endpoints vary by stage. Reviewing them together allows the agency to consider product quality, safety, and effectiveness rather than treating clinical results as the only evidence.
Statistical monitoring does not end when a product receives approval. Post-approval monitoring continues to examine evidence after the initial decision, allowing regulators to update their understanding of benefits and risks as additional information becomes available. This ongoing role is important because approval rests on evidence collected for an intended use, while later data can provide further context for public-health protection.